Formycon Shares Jump 13% After FDA Accepts Keytruda Biosimilar Application
Formycon and Zydus Lifesciences said the FDA accepted their application for review of a biosimilar version of Merck’s Keytruda. Formycon shares were up 13% in Europe.
S. Food and Drug Administration had accepted their application for review. The application seeks approval for a biosimilar version of Merck’s cancer drug Keytruda. Formycon shares were up 13% in Europ…